XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
RESTRUCTURING AND RELATED ACTIVITIES
9 Months Ended
Sep. 30, 2021
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND RELATED ACTIVITIES RESTRUCTURING AND RELATED ACTIVITIES
On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the “Restructuring Plan”).

The Restructuring Plan included a reduction in the Company’s workforce by 18 positions (or approximately 35% of the Company’s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan:
September 30,
2021
(in thousands)
Severance and benefits costs$2,792 
Contract termination costs2,730
Other restructuring costs— 
Total restructuring costs$5,522 
Cash payments(856)
Balance at September 30, 2021$4,666 

Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company’s Condensed Consolidated Statements of Income (Operations) and Comprehensive Income (Loss) in the three months ended September 30, 2021. The Company expects that substantially all of the accrued restructuring costs as of September 30, 2021 will be paid in cash by the end of September 2022.